Drug Approval | June 29, 2025
Briefs: Neuland Laboratories and Granules India
Granules India receives 1 observation from USFDA for Chantilly facility
Granules India receives 1 observation from USFDA for Chantilly facility
The company has posted net profit of Rs. 260.10 crores for the Financial Year ended March 31, 2025
The FDA issued Form 483 with one observation related to building and facility management
Prior to joining Neuland, Deshmukh held several key positions at Cipla
The company plans to fund this Capex through debt and internal accruals and expects the project to be completed by FY27
Neuland Laboratories has reported total income of Rs. 315.17 crores during the period ended September 30, 2024
The inspections concluded with no Form 483 observations or significant critical findings
The new brand identity embodies Neuland's unwavering commitment to innovation, integrity, collaboration, and progress
Neuland Laboratories has reported total income of Rs. 390.36 crores during the period ended March 31, 2024
The inspection at Unit 1 by the USFDA has been successfully completed, with no observations under Form 483
Subscribe To Our Newsletter & Stay Updated
